Leadership Change at Augustine Therapeutics
Augustine Therapeutics is thrilled to announce that Gerhard Koenig, PhD, has been appointed as the new Chief Executive Officer (CEO). This decision comes as the Company gears up to advance its innovative therapies into the clinical stage. Previously serving as Executive Chairman, Dr. Koenig's leadership is set to steer Augustine towards significant growth and achievement in the biopharmaceutical field.
Dr. Gerhard Koenig's Background
Dr. Koenig is not new to the world of biotechnology; he brings over three decades of rich experience in drug development. Since joining Augustine Therapeutics as a Non-Executive Director in 2022 and transitioning to Executive Chairman in 2024, he has played a crucial role in shaping the future of the Company. Before his tenure at Augustine, he co-founded Arkuda Therapeutics, focusing on neurodegenerative diseases such as Alzheimer’s and Parkinson’s. The valuable insights and expertise he gained at Arkuda will undoubtedly benefit Augustine.
Academic and Corporate Expertise
Throughout his illustrious career, Dr. Koenig has held key positions across various renowned organizations. His previous roles include serving as CEO of Quartet Medicine and Vice President of Scientific Programs at Fidelity Biosciences Group. His extensive experience in research and development, along with his proficiency in creating successful biopharma collaborations, positions him ideally for leading Augustine’s strategic initiatives.
Augustine Therapeutics: A New Chapter
As Augustine Therapeutics embarks on this new chapter, the Company is fiercely dedicated to building a portfolio of therapies that target severe neuromuscular, neurodegenerative, and cardiometabolic diseases. The primary focus remains on the development of small molecule inhibitors for HDAC6, an enzyme recognized for its role in various disease pathologies. These innovations place Augustine at the forefront of addressing unmet medical needs.
Focus on HDAC6 Inhibition
Augustine’s pipeline encompasses a variety of HDAC6 inhibitors aimed at revolutionizing treatment protocols. With the lead candidate, AGT100216, preparing for clinical trials in the context of Charcot-Marie-Tooth disease, the Company’s ambitions are clear: to create effective and disease-modifying therapies that can significantly improve patients' lives.
Impact of Dr. Koenig's Appointment
Commenting on his new role as CEO, Dr. Koenig expressed enthusiasm about leading Augustine's transition into a clinical-stage company. He acknowledged the tremendous potential that Augustine's HDAC6 inhibitors exhibit and emphasized the importance of collaboration within the team. His vision focuses on advancing the pipeline and fostering therapeutic advancements to address high unmet medical needs.
Support from the Board of Directors
Clara Campàs, Ph.D., a director at Augustine and Managing Partner at Asabys, extended her support for Dr. Koenig’s leadership. She highlighted his instrumental role during his time as Executive Chairman and expressed confidence in his capability to guide Augustine through its next critical phases of development.
About Augustine Therapeutics
Founded in 2019 as a spin-off from VIB-KU Leuven, Augustine Therapeutics is on a mission to tackle severe diseases through innovative biotechnology. The groundwork for the Company's research stems from pioneering studies led by Prof. Ludo Van Den Bosch, emphasizing the significance of selective HDAC6 inhibition in treating conditions that currently have limited therapeutic options. For further insights into Augustine's offerings, please visit www.augustinetx.com.
Frequently Asked Questions
Who is the new CEO of Augustine Therapeutics?
Dr. Gerhard Koenig has been appointed as the new CEO.
What experience does Dr. Koenig bring?
Dr. Koenig has over 30 years in drug development and previously co-founded Arkuda Therapeutics.
What is Augustine Therapeutics focused on?
Augustine focuses on developing innovative therapies for neuromuscular, neurodegenerative, and cardiometabolic diseases.
What is the lead candidate in Augustine’s pipeline?
AGT100216 is Augustine's lead candidate poised to enter clinical trials for Charcot-Marie-Tooth disease.
How does HDAC6 inhibition relate to disease treatment?
HDAC6 inhibition is believed to address the underlying mechanisms of several neurodegenerative and neuromuscular disorders.
